Retatrutide is an investigational peptide drug developed by Eli Lilly that acts as a triple agonist, simultaneously targeting three hormone receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors
Viewers should use discretion, seek professional advice when needed, and verify information independently
Although several anti-angiogenic drugs have been approved, intrinsic and acquired resistance to therapy limit their efficacy
We screened publicly available single nucleus RNAseq (snRNA-seq) datasets generated by Leng et al
(193) compared the effectiveness of three types of migraine medications: magnesium and sodium valproate, sodium valproate alone, and magnesium alone
Key Advantages: Minimal side effects, promotes natural GH release, no cortisol spike